{"name":"NS Pharma, Inc.","slug":"ns-pharma-inc","ticker":"","exchange":"","domain":"nspharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxPWVVibmYxNmNxZmptLUl6OXBTRXluMUpEWkY2SXJtbmd0bmRadVRRMTdIZ0VDVTdSSHpxdWpGdlVyLTBubThMbHU2WjB4OVVjTGVreEJkd2Fjei03YXhiM3pJZC1DQ0xqa1UtbXVPQl9kMks4WG9BaWNyekh0QkFCbFdvVWlMYXplMi05SFdwWDI2djNJNWs0UklwNHJidDZNVGg2UDlkSUJCNVdyX1VkYS01TW5wQ2p4cTE4V3VzTUZWQ1RjaWZNVTI1c3M2c3NQYzlNbmNTYnQ3UjZwMnU1c0hUNVZIUGhBTVhzRmZwcjVRV293cGNRVGVzSmQwUEhmYUtDUEp5RlRkcDdWWnB4cl8wbjdSYkdNb3hRRXV2SUxFS2laLUpEWGo3VDhuMUdvenB5MURCcTQ?oc=5","date":"2026-03-09","type":"trial","source":"PR Newswire","summary":"Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 MDA Clinical & Scientific Conference - PR Newswire","headline":"Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQa213SERnbGNZLWJfZUJiMW40NTZxYjhybGxkNzhVQlBxWWtlZkxidDUtNUF5QTZlY1JILVo2Y20zQzhKUjRuT2ZXTlRDSlZuSVBwaG04bEdtNC1GMGxJeGpqSGp2ZUVNUlMtLXd1SVVaYkZBUnhKRmdXZW9zZk16Tjk4cHR6NEZSZ0l6cHUwRXhPZkJDdlM5aVVRam9GRTlCa080?oc=5","date":"2025-10-16","type":"pipeline","source":"Muscular Dystrophy News","summary":"Duchenne MD therapy brogidirsen shows long-term benefit in boys - Muscular Dystrophy News","headline":"Duchenne MD therapy brogidirsen shows long-term benefit in boys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQQWkwc0oza2FkT3VEZUl3ZGRPZEY2VkZmS3VIQ3RTdDRKQ3c5cEVXV3RvYVZDSmxzVU5ncUZ5bVVvNDBBMEhCTjRaY2tQdlFBY2NXekpvQ0FXME05djJuSmJ4TE1pbTVrbEpCV1d2d24zV2dmQ21fTGVwaE1DQjhGekI4U21SNUVQMHBDbWg5TQ?oc=5","date":"2025-10-09","type":"pipeline","source":"Yahoo Finance","summary":"Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - ","headline":"Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOSXc0dnAyTUFBWF9vNnZ6S0FRQS1QM05EcXBlYW1NVnMzSGNWM05TQWJ5aWZ3dllZMTd1T2NJc0xfUmtYMDVIcHNoQVhSUkpXdXNDX0p6ejZCUUVSaEpmenk4WWd1bmx3SW4teElKV1lvQVNGdzFFLWMyN1owRGhlS2U0bHZtRUQtTFZqN19OT1dQZjQ?oc=5","date":"2025-09-22","type":"pipeline","source":"BioWorld News","summary":"NS Pharma’s NS-051 designated orphan drug for DMD - BioWorld News","headline":"NS Pharma’s NS-051 designated orphan drug for DMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNeHhTa0tkeUxGWm9FVkxxaUN1V2FiQ0xfX29FQndTN1dhM0NZVDJRQk1pZXkzZk41b0xMekJtNnZYQnh6OHUtczVEX2R3N2JlakRRWGItUWhOTVFHN0xjU243T2UzQVFUTEtmY1hYT1JkZVhTR3hNTTg0MEs3N05MY194Uzdid0RWbUVrTWh6Qi1OOFY1TGhGd09nd3oxZTR6cmw2eWFTSlJjMm1iTi1MZzVZMVpZTS1pZUNyTDM4Tm94TjE5R21rSFl2dUsxNVo0OGlZWWZoajBZOHY0NVRUVkQ1T3c5emkwS2VobTF3?oc=5","date":"2025-09-19","type":"regulatory","source":"PR Newswire","summary":"FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy - PR Newswire","headline":"FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOZjlGcFF1NGZRNjNHNnc0RkxMa2ROckhqOXhlSVU4WGktYklnOHN1NmYyNVBxNmhtMFAtcXRLckFQQjhpd05ZbTlpREFWU3hjeXFoZHdscHJBdTg2c2JweTNxVk5sWmt3MjBYdmxZcnZqakh0UzhXV1dkYlhwS01TejRLbnoyaUQtQ2M2elhyNlpOQWpRdGpza0lhUGl5NUNxYWktYmJvdGd0cllfeHV2clplU2pKZ1VnZThwb0VYMlRxdVFvVXJ6anY2eWhxY2h1am5uNEFrZVRya291T2pRVlRMVEV6Y0VUWkFyZnRMNkFGRWdxTVV2VEtn?oc=5","date":"2025-09-09","type":"regulatory","source":"PR Newswire","summary":"FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis - PR Newswire","headline":"FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNSkVJS3F6SXVyZDVKWlBObXRMMzE1S2dHUmtDMFdQX3dKRFdYV2RWOG1yTlA4V0JSRjRzUHkyT3Bvb3hSbnVFQnJMcVRXUFUxMmtEekZneTVGT3hYVzNQX1lvVTRiank1Yl8xWEVpMl9CcDdfRHp4UlJucE1mcUlycV92N2doc0JjLWoxTW80ZEc?oc=5","date":"2025-08-25","type":"regulatory","source":"CGTLive®","summary":"FDA Bumps Back PDUFA for REGENXBIO's MPS II Gene Therapy RGX-121 - CGTLive®","headline":"FDA Bumps Back PDUFA for REGENXBIO's MPS II Gene Therapy RGX-121 - CGTLive®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNZGRTaUtseVVrRElVdG1WSTRUWUMyMXd3OUVjTzJWREo5LVZZLXQ3UjdyTHNrTVJrems4dEtwNXB1OEM2cFJua0Q0TWE0R1hfWlNFdjNuREltb1pqODJadkloTDdhNFdDY3hVYlJ5aGVzeG1tNVFrNkl6TWpIZVNZNjdzNzR6Tm53WldYekF4QjNKTHJHbTRGZGpiank2NWNCbU1HOExDZ1MtTzBibHl0SUJhanZFQ2RVZUxnWVVEUFN5MUhsU19SSTdvOWZrb1RheGJxLXJVUWxLMXdDZm16V2E1VDZ0ZGtwZ0RJUllHelFiR19YWG5aanhDakw?oc=5","date":"2025-07-01","type":"pipeline","source":"PR Newswire","summary":"NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases - PR Newswire","headline":"NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPeFJNdmlJVF9pVmVYc0JzbVZ0YUFscWc1bUhZOVMxNTBnOENoVHVOSFktWDJIVEY0M0J6VkR2SEo2emZ3WkczbmNmdWlma2FwX2VxX3VYRnZpX1o1QXo2NURlX1BMYnlZNUQybksxTmJld3J3dVI0OFhfdnFFejJwU04zNThnbzAyX1hCV2haWE9KMVU?oc=5","date":"2024-05-28","type":"trial","source":"BioSpace","summary":"NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial - BioSpace","headline":"NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOdEdNU3VJS3NLTE93M0ZjTFNzUVEwNm9tMC1jWWhpZkJRcnMxbFRsVnc3VzFSa2tiTEc2dHpweGQyOHBwVjJkQ0JzUTMtYUU2TlprRGtfcG8xQ0VRTTVvb2E3d0ZISk1BbFV6OUwzUGhfVkVYLWhMOFFtMDdxNEw5cFBId3AtNl9FaVZZLUd6eVVYdXJFczFDRlJERHp0eE0?oc=5","date":"2023-11-28","type":"pipeline","source":"Muscular Dystrophy News","summary":"NS Pharma opens Duchenne Heroes to share first-person insights - Muscular Dystrophy News","headline":"NS Pharma opens Duchenne Heroes to share first-person insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQbGtzWEh1el9VOWxsXzg0d1RQcEFRQkgxcUxPc2dDNHdDZ1RrT1FWYjI0enJDQ1NtZW80MXZwdmdaZHdmZDVwZ3dxYW9STWlBeGJBRXE2X3pBUHlfQkk3NFZhQkxPRUtkcmxlY1dDcC1lNmc4Qjdob0xyYzExeDE3MkJGZTlGdXFIa01lUGxkWWJfQ245eFhVZ2k1cWRvazl3aDVUcFVzRQ?oc=5","date":"2023-08-04","type":"regulatory","source":"NeurologyLive","summary":"FDA Clears NS-050/NCNP-03 for Phase 1/2 Trial of Duchenne Muscular Dystrophy - NeurologyLive","headline":"FDA Clears NS-050/NCNP-03 for Phase 1/2 Trial of Duchenne Muscular Dystrophy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}